TY  - JOUR
AU  - Stanić, Dušanka
AU  - Plećaš-Solarović, Bosiljka
AU  - Mirković, Duško
AU  - Jovanović, Predrag
AU  - Dronjak, Slađana
AU  - Marković, Bojan
AU  - Dondević, Tea
AU  - Ignjatović, Svetlana
AU  - Pešić, Vesna
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3012
AB  - Chronic stress conditions can lead to considerable and extensible changes in physiological and psychological performances, and in emergence of risk for various somatic diseases. On the other hand, the neuropeptide oxytocin is reported to increase the resistance of the organism to stress and modulate activity of autonomic nervous system. Chronic corticosterone administration is used as a rat model for a state observed in terms of chronic stress exposure, when negative feedback mechanism of hypothalamus-pituitary-adrenal axis activity is disrupted. In our study, we aimed to investigate whether chronic administration of oxytocin (10114400 pI/day for 14 days, s.c.) influenced adrenal gland morphology and activity in adult male Wistar rats during long-term corticosterone administration via drinking water (100 mg/L for 21 days). We examined the influence of treatments on the levels of adrenal gland hormones, corticosterone, adrenaline and noradrenaline, as well as their response to an acute stress challenge evoked by 15-min forced swimming. In addition, the expression of two main monoamine transporters, the noradrenaline transporter (NAT) and vesicular monoamine transporter 2 (VMAT2) in adrenal medulla was measured in the rats exposed to acute stress. Our results showed that oxytocin treatment prevented corticosterone-induced decrease in body weight gain, attenuated adrenal gland atrophy by increasing glandular weight, and the area of the zona fasciculate and reticularis. Chronic corticosterone intake blunted the response of all measured hormones to acute stress, whereas concomitant oxytocin treatment reversed adrenaline and noradrenaline response to acute stress. Furthermore, in adrenal medulla, oxytocin produced significant vasodilatation and stimulated expression of both catecholamine transporters detected both on mRNA and protein level. Our data suggest that oxytocin, by reducing atrophy of adrenal gland, and by increasing catecholamine storage capacity, may be beneficial in conditions accompanied with high glucocorticoid levels, such as chronic stress exposure.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Psychopharmacology
T1  - Oxytocin in corticosterone-induced chronic stress model: Focus on adrenal gland function
VL  - 80
SP  - 137
EP  - 146
DO  - 10.1016/j.psyneuen.2017.03.011
ER  - 

@article{
author = "Stanić, Dušanka and Plećaš-Solarović, Bosiljka and Mirković, Duško and Jovanović, Predrag and Dronjak, Slađana and Marković, Bojan and Dondević, Tea and Ignjatović, Svetlana and Pešić, Vesna",
year = "2017",
abstract = "Chronic stress conditions can lead to considerable and extensible changes in physiological and psychological performances, and in emergence of risk for various somatic diseases. On the other hand, the neuropeptide oxytocin is reported to increase the resistance of the organism to stress and modulate activity of autonomic nervous system. Chronic corticosterone administration is used as a rat model for a state observed in terms of chronic stress exposure, when negative feedback mechanism of hypothalamus-pituitary-adrenal axis activity is disrupted. In our study, we aimed to investigate whether chronic administration of oxytocin (10114400 pI/day for 14 days, s.c.) influenced adrenal gland morphology and activity in adult male Wistar rats during long-term corticosterone administration via drinking water (100 mg/L for 21 days). We examined the influence of treatments on the levels of adrenal gland hormones, corticosterone, adrenaline and noradrenaline, as well as their response to an acute stress challenge evoked by 15-min forced swimming. In addition, the expression of two main monoamine transporters, the noradrenaline transporter (NAT) and vesicular monoamine transporter 2 (VMAT2) in adrenal medulla was measured in the rats exposed to acute stress. Our results showed that oxytocin treatment prevented corticosterone-induced decrease in body weight gain, attenuated adrenal gland atrophy by increasing glandular weight, and the area of the zona fasciculate and reticularis. Chronic corticosterone intake blunted the response of all measured hormones to acute stress, whereas concomitant oxytocin treatment reversed adrenaline and noradrenaline response to acute stress. Furthermore, in adrenal medulla, oxytocin produced significant vasodilatation and stimulated expression of both catecholamine transporters detected both on mRNA and protein level. Our data suggest that oxytocin, by reducing atrophy of adrenal gland, and by increasing catecholamine storage capacity, may be beneficial in conditions accompanied with high glucocorticoid levels, such as chronic stress exposure.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Psychopharmacology",
title = "Oxytocin in corticosterone-induced chronic stress model: Focus on adrenal gland function",
volume = "80",
pages = "137-146",
doi = "10.1016/j.psyneuen.2017.03.011"
}

Stanić, D., Plećaš-Solarović, B., Mirković, D., Jovanović, P., Dronjak, S., Marković, B., Dondević, T., Ignjatović, S.,& Pešić, V.. (2017). Oxytocin in corticosterone-induced chronic stress model: Focus on adrenal gland function. in Psychopharmacology
Pergamon-Elsevier Science Ltd, Oxford., 80, 137-146.
https://doi.org/10.1016/j.psyneuen.2017.03.011

Stanić D, Plećaš-Solarović B, Mirković D, Jovanović P, Dronjak S, Marković B, Dondević T, Ignjatović S, Pešić V. Oxytocin in corticosterone-induced chronic stress model: Focus on adrenal gland function. in Psychopharmacology. 2017;80:137-146.
doi:10.1016/j.psyneuen.2017.03.011 .

Stanić, Dušanka, Plećaš-Solarović, Bosiljka, Mirković, Duško, Jovanović, Predrag, Dronjak, Slađana, Marković, Bojan, Dondević, Tea, Ignjatović, Svetlana, Pešić, Vesna, "Oxytocin in corticosterone-induced chronic stress model: Focus on adrenal gland function" in Psychopharmacology, 80 (2017):137-146,
https://doi.org/10.1016/j.psyneuen.2017.03.011 . .

TY  - CONF
AU  - Stanić, Dušanka
AU  - Petrović, Jelena
AU  - Mirković, Duško
AU  - Đorđević, Tea
AU  - Durić, V.
AU  - Jovanović, P.
AU  - Dronjak, Slađana
AU  - Pešić, Vesna
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2686
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Oxytocin modulates HPA axis activity and hormone response to stress in rats chronically treated with corticosterone
VL  - 26
IS  - Supplement 2
SP  - S204
EP  - S204
DO  - 10.1016/S0924-977X(16)31048-3
ER  - 

@conference{
author = "Stanić, Dušanka and Petrović, Jelena and Mirković, Duško and Đorđević, Tea and Durić, V. and Jovanović, P. and Dronjak, Slađana and Pešić, Vesna",
year = "2016",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Oxytocin modulates HPA axis activity and hormone response to stress in rats chronically treated with corticosterone",
volume = "26",
number = "Supplement 2",
pages = "S204-S204",
doi = "10.1016/S0924-977X(16)31048-3"
}

Stanić, D., Petrović, J., Mirković, D., Đorđević, T., Durić, V., Jovanović, P., Dronjak, S.,& Pešić, V.. (2016). Oxytocin modulates HPA axis activity and hormone response to stress in rats chronically treated with corticosterone. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 26(Supplement 2), S204-S204.
https://doi.org/10.1016/S0924-977X(16)31048-3

Stanić D, Petrović J, Mirković D, Đorđević T, Durić V, Jovanović P, Dronjak S, Pešić V. Oxytocin modulates HPA axis activity and hormone response to stress in rats chronically treated with corticosterone. in European Neuropsychopharmacology. 2016;26(Supplement 2):S204-S204.
doi:10.1016/S0924-977X(16)31048-3 .

Stanić, Dušanka, Petrović, Jelena, Mirković, Duško, Đorđević, Tea, Durić, V., Jovanović, P., Dronjak, Slađana, Pešić, Vesna, "Oxytocin modulates HPA axis activity and hormone response to stress in rats chronically treated with corticosterone" in European Neuropsychopharmacology, 26, no. Supplement 2 (2016):S204-S204,
https://doi.org/10.1016/S0924-977X(16)31048-3 . .